rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2024-564-569rsp-3644Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCLINICAL OBSERVATIONСистемная красная волчанка и опоясывающий герпес (описание клинических наблюдений)Systemic lupus erythematosus and herpes zoster: Difficulties of curation (description of clinical observations)https://orcid.org/0000-0003-1318-1894ШумиловаА. А.ShumilovaA. A.

Шумилова Анастасия Александровна

115522, Москва, Каширское шоссе, 34а

Anastasiia Shumilova

115522, Moscow, Kashirskoye Highway, 34A

dr.anashumilova@gmail.comhttps://orcid.org/0000-0001-5217-4932ЧельдиеваФ. А.CheldievaF. A.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-6399-8766ТравкинаЕ. И.TravkinaE. I.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-6629-3374ЕвсиковаМ. Д.EvsikovaM. D.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-1663-7810АсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

https://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34а

125993, Москва, ул. Баррикадная, 2/1, стр. 1

115522, Moscow, Kashirskoye Highway, 34A

125993, Moscow, Barrikadnaya str., 2/1, building 1

https://orcid.org/0000-0003-3552-2522РешетнякТ. М.ReshetnyakT. M.

115522, Москва, Каширское шоссе, 34а

125993, Москва, ул. Баррикадная, 2/1, стр. 1

115522, Moscow, Kashirskoye Highway, 34A

125993, Moscow, Barrikadnaya str., 2/1, building 1

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationRussian Federation202401112024625564569Copyright © Шумилова А.А., Чельдиева Ф.А., Травкина Е.И., Евсикова М.Д., Асеева Е.А., Лила А.М., Решетняк Т.М., 20242024Шумилова А.А., Чельдиева Ф.А., Травкина Е.И., Евсикова М.Д., Асеева Е.А., Лила А.М., Решетняк Т.М.Shumilova A.A., Cheldieva F.A., Travkina E.I., Evsikova M.D., Aseeva E.A., Lila A.M., Reshetnyak T.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3644

Пациенты с системной красной волчанкой (СКВ) имеют повышенный риск развития опоясывающего герпеса (ОГ; herpes zoster). Сложности вакцинации у них возникают из-за возможного влияния на ее эффективность применяемой терапии глюкокортикоидами, базисными противовоспалительными препаратами и генно-инженерными биологическими препаратами. Приведено описание двух клинических наблюдений за пациентами, у которых на фоне активной СКВ и терапии иммуносупрессивными препаратами развился тяжелый ОГ. Обсуждается вопрос необходимости вакцинации в России против варицелла-зостер вируса пациентов, получающих иммуносупрессивную терапию.

Patients with systemic lupus erythematosus (SLE) have an increased risk of developing herpes zoster (HZ). Vaccination difficulties arise in these patients due to possible interactions with the therapy used with glucocorticoids, disease-modifying antirheumatic drugs and biologic disease-modifying anti-rheumatic drugs. The description of two clinical observations of patients with SLE, who developed severe HZ against the background of active SLE and therapy with immunosuppressive drugs, is given. The issue of the need for vaccination in Russia against varicella zoster virus of patients on immunosuppressive therapy is discussed.

системная красная волчанкаинфекцииопоясывающий герпесsystemic lupus erythematosusinfectionsherpes zosterСтатья подготовлена в рамках темы ФГБНУ «НИИР им. В.А. Насоновой» 122040400024-7.ReferencesБадокин ВВ (ред.). Ревматология. Клинические лекции. М.:Литтера;2012Badokin VV (ed.). Rheumatology. Clinical lectures. Moscow:Littera;2012 (In Russ.).Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043-1053. doi: 10.1080/1744666X.2018.1538789Ocampo-Piraquive V, Nieto-Aristizábal I, Cañas CA, Tobón GJ. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. Expert Rev Clin Immunol. 2018;14(12):1043-1053. doi: 10.1080/1744666X.2018.1538789Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. Allcause and cause-specific mortality in systemic lupus erythematosus: A population-based study. Rheumatology (Oxford). 2021;61(1):367-376. doi: 10.1093/rheumatology/keab362Moghaddam B, Marozoff S, Li L, Sayre EC, Zubieta JAA. Allcause and cause-specific mortality in systemic lupus erythematosus: A population-based study. Rheumatology (Oxford). 2021;61(1):367-376. doi: 10.1093/rheumatology/keab362Schmader K. Herpes zoster. Ann Intern Med. 2018;169(3):ITC19-ITC31. doi: 10.7326/AITC201808070Schmader K. Herpes zoster. Ann Intern Med. 2018;169(3):ITC19-ITC31. doi: 10.7326/AITC201808070Ehrenstein B. Diagnostik, Therapie und Prophylaxe des Herpes zoster [Diagnosis, treatment and prophylaxis of herpes zoster. Z Rheumatol. 2020;79(10):1009-1017 (In German). doi: 10.1007/s00393-020-00915-yEhrenstein B. Diagnostik, Therapie und Prophylaxe des Herpes zoster [Diagnosis, treatment and prophylaxis of herpes zoster. Z Rheumatol. 2020;79(10):1009-1017 (In German). doi: 10.1007/s00393-020-00915-yForbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911. doi: 10.1136/bmj.g2911Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348:g2911. doi: 10.1136/bmj.g2911Kawai K, Yawn BP. Risk factors for herpes zoster: A systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806-1821. doi: 10.1016/j.mayocp.2017.10.009Kawai K, Yawn BP. Risk factors for herpes zoster: A systematic review and meta-analysis. Mayo Clin Proc. 2017;92(12):1806-1821. doi: 10.1016/j.mayocp.2017.10.009Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: A meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi: 10.1093/ofid/ofaa005Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: A meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi: 10.1093/ofid/ofaa005Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: Data from the German RABBIT register. Ann Rheum Dis. 2022;81(1):41-47. doi: 10.1136/annrheumdis-2021-220651Redeker I, Albrecht K, Kekow J, Burmester GR, Braun J, Schäfer M, et al. Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: Data from the German RABBIT register. Ann Rheum Dis. 2022;81(1):41-47. doi: 10.1136/annrheumdis-2021-220651Curtis J, Yang S, Chen L, Winthrop K, Xie F, Baddley JW, et al. FRI0193 Herpes zoster infection across auto-immune and inflammatory diseases: Implications for vaccination. Ann Rheum Dis. 2014;73:452. doi: 10.1136/annrheumdis-2014-eular.5983Curtis J, Yang S, Chen L, Winthrop K, Xie F, Baddley JW, et al. FRI0193 Herpes zoster infection across auto-immune and inflammatory diseases: Implications for vaccination. Ann Rheum Dis. 2014;73:452. doi: 10.1136/annrheumdis-2014-eular.5983Шумилова АА, Решетняк ТМ, Чельдиева ФА, Лила АМ. Трудности ведения больных системной красной волчанкой и антифосфолипидным синдромом в сочетании с меланомой и инфильтративным туберкулезом (клинические наблюдения). Современная ревматология. 2021;15(4):87-93.Shumilova AA, Reshetnyak TM, Cheldieva FA, Lila AM. Difficulties in management of patients with systemic lupus erythematosus and antiphospholipid syndrome in combination with melanoma and infiltrative tuberculosis (clinical observations). Modern Rheumatology Journal. 2021;15(4):87-93 (In Russ.). doi: 10.14412/1996-7012-2021-4-87-93Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: The current status. Hum Vaccin Immunother. 2019;15(1):45-48. doi: 10.1080/21645515.2018.1514228Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: The current status. Hum Vaccin Immunother. 2019;15(1):45-48. doi: 10.1080/21645515.2018.1514228Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: Prevalence, incidence and risk factors. Lupus Sci Med. 2022;9(1):e000574. doi: 10.1136/lupus-2021-000574Kwan A, Rayes HA, Lazova T, Anderson N, Bonilla D, Su J, et al. Herpes zoster in SLE: Prevalence, incidence and risk factors. Lupus Sci Med. 2022;9(1):e000574. doi: 10.1136/lupus-2021-000574Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328-2337. doi: 10.1002/art.39670Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol. 2016;68(9):2328-2337. doi: 10.1002/art.39670Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. doi: 10.1002/art.27233Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222-233. doi: 10.1002/art.27233Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382(3):211-221. doi: 10.1056/NEJMoa1912196Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al.; TULIP-1 study investigators. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al.; TULIP-1 study investigators. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): A randomised, controlled, phase 3 trial. Lancet Rheumatol. 2019;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1Dagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-XDagnew AF, Ilhan O, Lee WS, Woszczyk D, Kwak JY, Bowcock S, et al.; Zoster-039 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: A phase 3, randomised, clinical trial and post-hoc efficacy analysis. Lancet Infect Dis. 2019;19(9):988-1000. doi: 10.1016/S1473-3099(19)30163-XLenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021;60(11):5149-5157. doi: 10.1093/rheumatology/keab139Lenfant T, Jin Y, Kirchner E, Hajj-Ali RA, Calabrese LH, Calabrese C. Safety of recombinant zoster vaccine: A retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021;60(11):5149-5157. doi: 10.1093/rheumatology/keab139Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333-348. doi: 10.1002/art.42386Bass AR, Chakravarty E, Akl EA, Bingham CO, Calabrese L, Cappelli LC, et al. 2022 American College of Rheumatology guideline for vaccinations in patients with rheumatic and musculoskeletal diseases. Arthritis Rheumatol. 2023;75(3):333-348. doi: 10.1002/art.42386Centers for Disease Control and Prevention. Altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html (Accessed: 01 August 2023).Centers for Disease Control and Prevention. Altered immunocompetence. URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html (Accessed: 01 August 2023).Белов БС, Муравьева НВ, Насонов ЕЛ. Вакцинация при ревматических заболеваниях: актуальные вопросы (по материалам рекомендаций ACR). Научно-практическая ревматология. 2023;61(2):151-157.Belov BS, Muravyeva NV, Nasonov EL. Vaccination for rheumatic diseases: Current issues (based on ACR guidelines). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(2):151-157 (In Russ.). doi: 10.47360/1995-4484-2023-151-157

The authors declare that there are no conflicts of interest present.